Characterization of a novel high-potency positive modulator of K v7 channels

European Journal of Pharmacology

Volumn 709, Issue 1-3, 2013, Pages 52-63

  Dalby Brown, William ^a   Jessen, Carsten ^a   Hougaard, Charlotte ^a   Jensen, Marianne L ^a   Jacobsen, Thomas A ^a   Nielsen, Karin S ^a   Erichsen, Helle K ^a   Grunnet, Morten ^a   Ahring, Philip K ^a   Christophersen, Palle ^a   Strøbæk, Dorte ^a   Jørgensen, Susanne ^a  

^a NEUROSEARCH A S   (Denmark)

Author keywords

Bipolar disorder; CA1 pyramidal neurons; Epilepsy; Neuronal Kv7 channel; NS15370; Retigabine

Indexed keywords

10,10 BIS(4 PYRIDINYLMETHYL) 9(10H) ANTHRACENONE; DIZOCILPINE; NS 15370; POTASSIUM CHANNEL KCNQ2; POTASSIUM CHANNEL KCNQ3; POTASSIUM CHANNEL KCNQ4; POTASSIUM CHANNEL KCNQ5; POTASSIUM CHANNEL STIMULATING AGENT; RETIGABINE; UNCLASSIFIED DRUG;

AFTERHYPERPOLARIZATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICONVULSANT ACTIVITY; ARTICLE; BINDING AFFINITY; BRAIN REGION; COMPLEX PARTIAL SEIZURE; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; DRUG BINDING SITE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; FEMALE; FOCAL EPILEPSY; HIPPOCAMPAL CA1 REGION; HUMAN; HUMAN CELL; HYPERACTIVITY; IC 50; LOCOMOTION; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SUBSTANTIA NIGRA PARS COMPACTA; TREATMENT RESPONSE;

AMINOPYRIDINES; ANIMALS; ANTICONVULSANTS; ANTIMANIC AGENTS; ANTIPSYCHOTIC AGENTS; BENZENEACETAMIDES; BIPOLAR DISORDER; CA1 REGION, HIPPOCAMPAL; DISEASE MODELS, ANIMAL; DOPAMINERGIC NEURONS; EPILEPSIES, PARTIAL; FEMALE; GABAERGIC NEURONS; HEK293 CELLS; HUMANS; KCNQ1 POTASSIUM CHANNEL; MALE; MEMBRANE TRANSPORT MODULATORS; MICE; NERVE TISSUE PROTEINS; PSYCHOTIC DISORDERS; RATS; RECOMBINANT PROTEINS; SUBSTANTIA NIGRA;

EID: 84877084123     PISSN: 00142999     EISSN: 18790712     Source Type: Journal    
DOI: 10.1016/j.ejphar.2013.03.039     Document Type: Article

References (48)

1. M.E. Barton, B.D. Klein, H.H. Wolf, and H.S. White Pharmacological characterization of the 6 Hz psychomotor seizure model of partial epilepsy Epilepsy Res. 47 2001 217 227
2. v7 (KCNQ) potassium channels Neuropharmacology 51 2006 1068 1077
3. M. Bialer, S.I. Johannessen, R.H. Levy, E. Perucca, T. Tomson, and H.S. White Progress report on new antiepileptic drugs: a summary of the Ninth Eilat Conference (EILAT IX) Epilepsy Res. 83 2009 1 43
4. C. Biervert, B.C. Schroeder, C. Kubisch, S.F. Berkovic, P. Propping, T.J. Jentsch, and O.K. Steinlein A potassium channel mutation in neonatal human epilepsy Science 279 1998 403 406
5. S.M. Blom, N. Schmitt, and H.S. Jensen The acrylamide (S)-2 as a positive and negative modulator of Kv7 channels expressed in Xenopus laevis oocytes PLoS One 4 2009 0008251 e8251, i:10.1371/journal.pone
6. v7) potassium channels Epilepsia 53 2012 606 612
7. + current in a vertebrate neurone Nature 283 1980 673 676
8. v7) channels Br. J. Pharmacol. 156 2009 1185 1195
9. S. Butini, S. Gemma, G. Campiani, S. Franceschini, F. Trotta, M. Borriello, N. Ceres, S. Ros, S.S. Coccone, M. Bernetti, M. De Angelis, M. Brindisi, V. Nacci, I. Fiorini, E. Novellino, A. Cagnotto, T. Mennini, K.S. Nielsen, J.T. Andreasen, J. Scheel-Kruger, J.D. Mikkelsen, and C. Fattorusso Discovery of a new class of potential multifunctional atypical antipsychotic agents targeting dopamine D3 and serotonin 5-HT1A and 5-HT2A receptors: design, synthesis, and effects on behavior J. Med. Chem. 52 2009 151 169
10. C. Charlier, N.A. Singh, S.G. Ryan, T.B. Lewis, B.E. Reus, R.J. Leach, and M. Leppert A pore mutation in a novel KQT-like potassium channel gene in an idiopathic epilepsy family Nat. Genet. 18 1998 53 55
11. Y.H. Chen, S.J. Xu, S. Bendahhou, X.L. Wang, Y. Wang, W.Y. Xu, H.W. Jin, H. Sun, X.Y. Su, Q.N. Zhuang, Y.Q. Yang, Y.B. Li, Y. Liu, H.J. Xu, X.F. Li, N. Ma, C.P. Mou, Z. Chen, J. Barhanin, and W. Huang KCNQ1 gain-of-function mutation in familial atrial fibrillation Science 299 2003 251 254
12. D. Dencker, R. Dias, M.L. Pedersen, and H. Husum Effect of the new antiepileptic drug retigabine in a rodent model of mania Epilepsy Behav. 12 2008 49 53
13. D. Dencker, and H. Husum Antimanic efficacy of retigabine in a proposed mouse model of bipolar disorder Behav. Brain. Res. 207 2010 78 83
14. D. Dupuis, R.L. Schrøder, T. Jespersen, J.K. Christensen, P. Christophersen, B.S. Jensen, and S.P. Olesen Activation of KCNQ5 channels stably expressed in HEK293 cells by BMS-204352 Eur. J. Pharmacol. 437 2002 129 137
15. C. Fattore, and E. Perucca Novel medications for epilepsy Drugs 71 2011 2151 2178
16. I.A. Greenwood, and S. Ohya New tricks for old dogs: KCNQ expression and role in smooth muscle Br. J. Pharmacol. 156 2009 1196 1203
17. Ca2/SK channels, contribute to the somatic medium after-hyperpolarization and excitability control in CA1 hippocampal pyramidal cells J. Physiol. 566 2005 689 715
18. H.H. Hansen, J.T. Andreasen, P. Weikop, N. Mirza, J. Scheel-Krüger, and J.D. Mikkelsen The neuronal KCNQ channel opener retigabine inhibits locomotor activity and reduces forebrain excitatory responses to the psychostimulants cocaine, methylphenidate and phencyclidine Eur. J. Pharmacol. 570 2007 77 88
19. H.H. Hansen, C. Ebbesen, C. Mathiesen, P. Weikop, L.C. Rønn, O. Waroux, J Scuvée-Moreau, Seutin, and J.D. Mikkelsen The KCNQ channel opener retigabine inhibits the activity of mesencephalic dopaminergic systems of the rat J. Pharmacol. Exp. Ther. 318 2006 1006 1019
20. + channels Br. J. Pharmacol. 151 2007 655 665
21. v7 channels Biophys. J. 92 2007 2747 2756
22. T.J. Jentsch Neuronal KCNQ potassium channels: physiology and role in disease Nat. Rev. Neurosci. 1 2000 21 30
23. T. Jespersen, M. Grunnet, and S.P. Olesen The KCNQ1 potassium channel: from gene to physiological function Physiology (Bethesda) 20 2005 408 416
24. v7 channels J. Pharmacol. Exp. Ther. 314 2005 282 292
25. S. Koyama, and S.B. Appel Characterization of M-current in ventral tegmental area dopamine neurons J. Neurophysiol. 96 2006 535 543
26. S. Koyama Primer effects by conspecific odors in house mice: a new perspective in the study of primer effects on reproductive activities Horm. Behav. 46 2004 303 310
27. C. Kubisch, B.C. Schroeder, T. Friedrich, B. Lütjohann, A. El-Amraoui, S. Marlin, C. Petit, and T.J. Jentsch KCNQ4, a novel potassium channel expressed in sensory outer hair cells, is mutated in dominant deafness Cell 96 1999 437 446
28. C.H. Large, D.M. Sokal, A. Nehlig, M.J. Gunthorpe, R. Sankar, C.S. Crean, K.E. Vanlandingham, and H.S. White The spectrum of anticonvulsant efficacy of retigabine (ezogabine) in animal models: implications for clinical use Epilepsia 53 2012 425 436
29. W. Löscher, and D. Schmidt Which animal models should be used in the search for new antiepileptic drugs? A proposal based on experimental and clinical considerations Epilepsy Res. 2 1988 145 181
30. W. Ma, Z. Miao, and M.V. Novotny Induction of estrus in grouped female mice (Mus domesticus) by synthetic analogues of preputial gland constituents Chem. Senses 24 1999 289 293
31. M.J. Main, J.E. Cryan, J.R. Dupere, B. Cox, J.J. Clare, and S.A. Burbidge Modulation of KCNQ2/3 potassium channels by the novel anticonvulsant retigabine Mol. Pharmacol. 58 2000 253 262
32. G. Munro, H.K. Erichsen, and N.R. Mirza Pharmacological comparison of anticonvulsant drugs in animal models of persistent pain and anxiety Neuropharmacology 53 2007 609 618
33. J.F. Otto, M.M. Kimball, and K.S. Wilcox Effects of the anticonvulsant retigabine on cultured cortical neurons: changes in electroresponsive properties and synaptic transmission Mol. Pharmacol. 61 2002 921 927
34. v7 potassium channel activators on hyperactivity in a rodent model of mania Behav. Brain Res. 198 2009 481 485
35. v7.3) activator in rodent anticonvulsant models J. Pharmacol. Exp. Ther. 326 2008 818 828
36. C. Rundfeldt, and R. Netzer Investigations into the mechanism of action of the new anticonvulsant retigabine. Interaction with GABAergic and glutamatergic neurotransmission and with voltage gated ion channels Arzneimittelforschung 50 2000 1063 1070
37. C. Rundfeldt, and R. Netzer The novel anticonvulsant retigabine activates M-currents in Chinese hamster ovary-cells tranfected with human KCNQ2/3 subunits Neurosci. Lett. 282 2000 73 76
38. R.L. Schrøder, T. Jespersen, P. Christophersen, D. Strøbæk, B.S. Jensen, and S.P. Olesen KCNQ4 channel activation by BMS-204352 and retigabine Neuropharmacology 40 2001 888 898
39. R. Søgaard, T. Ljungstrøm, K.A. Pedersen, S.P. Olesen, and B.S. Jensen KCNQ4 channels expressed in mammalian cells: functional characteristics and pharmacology Am. J. Physiol. Cell. Physiol. 280 2001 C859 C866
40. F. Sotty, T. Damgaard, L.P. Montezinho, A. Mørk, C.K. Olsen, C. Bundgaard, and H. Husum Antipsychotic-like effect of retigabine [N-(2-Amino-4-(fluorobenzylamino)-phenyl)carbamic acid ester], a KCNQ potassium channel opener, via modulation of mesolimbic dopaminergic neurotransmission J. Pharmacol. Exp. Ther. 328 2009 951 962
41. B.C. Suh, and B. Hille Recovery from muscarinic modulation of M current channels requires phosphatidylinositol 4,5-bisphosphate synthesis Neuron 35 2002 507 520
42. L. Tatulian, P. Delmas, F.C. Abogadie, and D.A. Brown Activation of expressed KCNQ potassium currents and native neuronal M-type potassium currents by the anti-convulsant drug retigabine J. Neurosci. 21 2001 5535 5545
43. C. Tober, A. Rostock, C. Rundfeldt, and R. Bartsch D-23129: a potent anticonvulsant in the amygdala kindling model of complex partial seizures Eur. J. Pharmacol. 303 1996 163 169
44. C.M. van Rijn, and E. Willems-van Bree Synergy between retigabine and GABA in modulating the convulsant site of the GABAA receptor complex Eur. J. Pharmacol. 464 2003 95 100
45. H.S. Wang, Z. Pan, W. Shi, B.S. Brown, R.S. Wymore, I.S. Cohen, J.E. Dixon, and D. McKinnon KCNQ2 and KCNQ3 potassium channel subunits: molecular correlates of the M-channel Science 282 1998 1890 1893
46. C.D. Weaver, D. Harden, S.I. Dworetzky, B. Robertson, and R.J. Knox A thallium-sensitive, fluorescence-based assay for detecting and characterizing potassium channel modulators in mammalian cells J. Biomol. Screen. 9 2004 671 677
47. A.D. Wickenden, J.L. Krajewski, B. London, P.K. Wagoner, W.A. Wilson, S. Clark, R. Roeloffs, G. McNaughton-Smith, and G.C. Rigdon N-(6-chloro-pyridin-3- yl)-3,4-difluoro-benzamide (ICA-27243): a novel, selective KCNQ2/Q3 potassium channel activator Mol. Pharmacol. 73 2008 977 986
48. A.D. Wickenden, W. Yu, A. Zou, T. Jegla, and P.K. Wagoner Retigabine, a novel anti-convulsant, enhances activation of KCNQ2/Q3 potassium channels Mol. Pharmacol. 58 2000 591 600